Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL3696191 | 0.95 | — | — | |
| Tromethamine SCHEMBL975 | 0.95 | — | — | |
| Tromethamine SCHEMBL17484 | 0.95 | MEN1 (1.00) | — | |
| Tromethamine SCHEMBL6427079 | 0.91 | — | — | |
| Tromethamine SCHEMBL445853 | 0.91 | MEN1 (0.91) | — | |
| Tromethamine SCHEMBL2035496 | 0.91 | — | — | |
| Tromethamine SCHEMBL9298764 | 0.91 | — | — | |
| Tromethamine SCHEMBL7126002 | 0.91 | — | — | |
| Tromethamine SCHEMBL112367 | 0.91 | — | — | |
| Tromethamine SCHEMBL11847711 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139577-A1 | LEVELS OF BCMA PROTEIN EXPRESSION ON B CELLS AND USE IN DIAGNOSTIC METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | ZYMOGENETICS, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-RE48370-E1 | Levels of BCMA protein expression on B cells and use in methods of treating systemic lupus erythematosus | ZYMOGENETICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10336820-B2 | Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof | AMGEN INC. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-2679599-B1 | Antibodies directed to Angiopoietin-1 and Angiopoietin-2 and use thereof | AMGEN INC (US) | 2018-01-03 | — | — | EP | disclosed |
| US-9725506-B2 | Levels of BCMA protein expression on B cells and use in methods of treating systemic lupus erythematosus | ZYMOGENETICS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9717649-B2 | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients | CORNING INCORPORATED (US) | 2017-08-01 | — | — | US | disclosed |
| EP-2796427-B1 | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients | CORNING INC (US) | 2017-06-07 | — | — | EP | disclosed |
| US-20170081398-A1 | ANTIBODIES DIRECTED TO ANGIOPOIETIN-1 AND ANGIOPOIETIN-2 AND USES THEREOF | AMGEN INC. | 2017-03-23 | — | — | US | disclosed |
| US-20160051671-A1 | COMBINATION OF BLyS INHIBITION AND ANTI-CD 20 AGENTS FOR TREATMENT OF AUTOIMMUNE DISEASE | ARES TRADING S.A. (CH) | 2016-02-25 | — | — | US | disclosed |
| EP-2233149-B1 | Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease | ZYMOGENETICS INC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-20090226447-A1 | Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof | AMGEN, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2009105269-A1 | ANTIBODIES DIRECTED TO ANGIOPOIETIN-1 AND ANGIOPOIETIN-2 AND USE THEREOF | AMGEN INC. (US) | 2009-08-27 | — | — | WO | disclosed |
| US-20090148442-A1 | COMBINATION OF BLyS INHIBITION AND ANTI-CD 20 AGENTS FOR TREATMENT OF AUTOIMMUNE DISEASE | ZYMOGENETICS, INC. | 2009-06-11 | — | — | US | disclosed |
| EP-1660135-B1 | METHOD OF TREATING HEPATOCELLULAR CARCINOMA | ZYMOGENETICS INC (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2009052293-A1 | COMBINATION OF BLYS INHIBITION AND ANTI-CD 20 AGENTS FOR TREATMENT OF AUTOIMMUNE DISEASE | ZYMOGENETICS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090028865-A1 | METHOD OF TREATING HEPATOCELLULAR CARCINOMA | ZYMOGENETICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20070054858-A1 | METHOD OF TREATING HEPATOCELLULAR CARCINOMA | ZYMOGENETICS, INC. | 2007-03-08 | — | — | US | disclosed |
| EP-1660135-A1 | METHOD OF TREATING HEPATOCELLULAR CARCINOMA | ZymoGenetics, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050191304-A1 | Method of treating hepatocellular carcinoma | ZYMOGENETICS, INC. | 2005-09-01 | — | — | US | disclosed |
| WO-2005011742-A1 | METHOD OF TREATING HEPATOCELLULAR CARCINOMA | ZYMOGENETICS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |